Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zepatier

- PMLiVE

Merck puts prostate cancer firmly in Keytruda’s sights

Lynparza combination could open up huge new market

- PMLiVE

Analysts look beyond Keytruda in Merck’s future

CEO Frazier made to defend pipeline prospects

- PMLiVE

NHS England sees off AbbVie’s Hep C legal challenge

Claims of unfair process dismissed by High Court

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

- PMLiVE

Merck exec steps down, two takes his place

Head of global human health Adam Schechter will transition to CEO advisor

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

- PMLiVE

AbbVie sues NHS England over hep C procurement

Accuses NHS of not treating all bidders fairly

- PMLiVE

Keytruda hits survival targets in first-line kidney cancer

New data presented at ESMO congress

- PMLiVE

Merck & Co picks Nike exec to be digital transformation leader

Cyber-security and customer focus will be key issues

- PMLiVE

Merck & Co joins big pharma pricing pledge – but sceptics unconvinced

Large portfolios gives companies room for manoeuvre

- PMLiVE

Merck’s Brexit contingency plan? Stockpile medicines

As UK's Brexit plans remain in disarray, big pharma is making contingency plans

- PMLiVE

ACT immunotherapy cures terminal breast cancer patient

The new approach focuses on mutations rather than cancer type

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links